Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
UznaAhKsFX6J0r1F